Houston-based Starlab Space has teamed up with Helogen Corporation to deploy the HEL-IOS biomedical operating system aboard the Starlab commercial space station. The deal, revealed February 18, targets a surge in low Earth orbit research demands. HEL-IOS will handle everything from biological cultivation and processing to sequencing and real-time analytics, all autonomously.

Starlab CEO Marshall Smith called the integration a game-changer for life sciences in space. “This partnership reflects exactly how we envision life sciences operating in low Earth orbit,” Smith said. He added that it shifts researchers from brief experiments to ongoing manufacturing workflows with tangible Earth benefits.

Helogen, which specializes in orbital automation, brings its flagship HEL-IOS platform to the table. Described as the world’s first orbital biomedical operating system, it promises regulatory-compliant biomanufacturing. Commercial partners stand to gain from scaled output with fewer launches and lower costs. Researchers, meanwhile, get automated pipelines free from crew dependencies or constant sample returns.

Microgravity offers unique advantages for drug development and beyond. Protein crystals grow larger and purer in orbit, aiding pharmaceuticals. Cells form three-dimensional structures mimicking human tissues more closely than on Earth. Disease models and stem cell studies could yield breakthroughs for Parkinson’s, diabetes and Alzheimer’s, according to company statements.

Helogen CEO Shishir Bankapur emphasized the model shift. “Microgravity is not just a research environment. It’s a fundamentally new manufacturing and discovery regime,” he said. “Our mission is to unlock biological processes that Earth’s gravity suppresses and translate them into scalable breakthroughs in medicine and materials.”

Starlab’s platform, designed for global access, pairs with HEL-IOS to speed up biology in space. The combo supports high-throughput discovery, moving past isolated tests on facilities like the International Space Station.

The ISS already hosts cell culture work to test drug responses in the human body. Plant biology experiments probe growth fundamentals. Stem cell differentiation studies track epigenetic influences. Even biomedical devices with fluids—from dialysis machines to glucose monitors—benefit from orbital testing.

This partnership arrives amid rapid space industry growth. Deloitte projects the sector will surpass $800 billion by 2027, fueled by more orbital launches each year. Starlab positions itself as a key player in low Earth orbit infrastructure, filling gaps left by retiring government stations.

With HEL-IOS online, Starlab could host persistent experiments in pharmaceuticals, regenerative medicine and crop science. Fewer flights mean lower overhead. Automated systems ensure consistent results. The result: faster iteration for scientists chasing gravity-defying innovations.

Both companies see orbit as the next frontier for industrial biology. Starlab provides the habitat. Helogen supplies the smarts. Together, they aim to industrialize space-based life sciences.